Quanterix Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Quanterix Corporation on August 17, 2020, regarding events occurring on August 14, 2020. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Billerica, MA. Its common stock trades on The Nasdaq Global Market under the symbol QTRX.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance and listing compliance matters.
Material Changes
- Board Resignation: John Connolly resigned from the Board of Directors and all committees, including the Audit Committee, effective August 14, 2020.
- Reason for Departure: The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Listing Non-Compliance: The resignation resulted in the Audit Committee having fewer than three independent directors, causing non-compliance with Nasdaq Listing Rule 5605(c)(2)(A).
Outlook, Risks, and Contingencies
Cure Period: The Company notified Nasdaq of the non-compliance and is entitled to a cure period to regain compliance. This period expires on the earlier of the next annual stockholders' meeting or August 14, 2021. If the next annual meeting is held on or before February 10, 2021, compliance must be achieved by that date.
Management Expectation: The Company expects to be compliant with the Audit Committee composition requirements by or before the end of the cure period.
Key Facts for Investor Verification
- Verify the timeline for appointing a new independent director to restore the Audit Committee to three members.
- Monitor subsequent filings to confirm the Company's compliance status before the cure period deadline.
- Confirm that no other undisclosed disagreements or operational issues are associated with Mr. Connolly's departure.